Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines

Fig. 1

Two-way sensitivity analysis of the vaccine cost per series of HZ/su and vaccine cost per dose of ZVL for vaccination of a 50-year-olds, b 60-year-olds, c 70-year-olds and d 80-year-olds. After performing a probabilistic sensitivity analysis using 10,000 Monte Carlo simulations, the alternative with the highest probability of being cost-effective to a willingness-to-pay threshold of €20,000 per QALY gained is presented over a range of vaccine cost. Dark coloured areas indicate that the probability of being the most cost-effective alternative is higher than 90%. HZ/su, herpes zoster subunit vaccine; QALY, quality-adjusted life year; ZVL, zoster vaccine live

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us